Aquablation therapy in large prostates (80–150 cc) for lower urinary tract symptoms due to benign prostatic hyperplasia: WATER II 3-year trial results

Kevin C. Zorn1 | Mohamed Bidair2 | Andrew Trainer3 | Andrew Arther3 | Eugene Kramolowsky4 | Mihir Desai5 | Leo Doumanian6 | Dean Elterman6 | Ronald P. Kaufman Jr.7 | James Lingeman8 | Amy Krambeck8 | Gregg Eure9 | Gopal Badlani10 | Mark Plante11 | Edward Uchio12 | Greg Gin12 | S. Larry Goldenberg13 | Ryan Paterson13 | Alan So13 | Mitchell Humphreys14 | Claus Roehrborn15 | Steven Kaplan16 | Jay Motola16 | Naeem Bhojani1

1University of Montreal Hospital Center, University of Montreal, Montréal, Québec, Canada
2Urology, San Diego Clinical Trials, San Diego, California, USA
3Urology, Adult Pediatric Urology & Urogynecology, P.C., Omaha, Nebraska, USA
4Urology, Virginia Urology, Richmond, Virginia, USA
5Institute of Urology, University of Southern California, Los Angeles, California, USA
6University Health Network, University of Toronto, Toronto, Ontario, Canada
7Urology, Albany Medical College, Albany, New York, USA
8Urology, Indiana University Health Physicians, Indianapolis, Indiana, USA
9Urology, Urology of Virginia, Virginia Beach, Virginia, USA
10Urology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA
11Urology, University of Vermont Medical Center, Burlington, Vermont, USA
12Urology, VA Long Beach Healthcare System, Long Beach, California, USA
13Urology, University of British Columbia, Vancouver, British Columbia, Canada
14Urology, Mayo Clinic Arizona, Scottsdale, Arizona, USA
15UT Southwestern Medical Center, Department of Urology, University of Texas Southwestern, Dallas, Texas, USA
16Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA

Correspondence
Kevin Zorn, Department of Urology, University of Montreal Hospital Center (CHUM), University of Montreal, 1051, rue Sainte-Catherine Ouest, Montréal, Québec H2X 3E4, Canada.
Email: zorn.chumurology@gmail.com

Funding information
PROCEPT BioRobotics Corporation

Abstract
Objective: The objective of this study is to determine if Aquablation therapy can maintain its effectiveness in treating men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) with large-volume (80–150 cc) prostates at 3 years.

Subjects and Methods: One hundred one men with moderate-to-severe BPH symptoms and prostate volumes between 80 and 150 cc were enrolled in a prospective,
INTRODUCTION

Increasing evidence supports the use of robotically executed waterjet-based resection of the prostate (Aquablation procedure) as an alternative to other tissue resection-based procedures for men with moderate-to-severe lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Prospective trials have shown excellent safety and effectiveness in men with smaller (30–80 cc)\(^1\) and larger (80–150 cc) prostates.\(^2,3\) Postmarket studies have confirmed these findings.\(^4,5\) Studies have shown persistent improvements in symptoms related to BPH, uroflow measures, and quality of life (QOL). Surgical revision rates have been found to be approximately 1% per year.\(^3,4,6\) Compared with TURP, the Aquablation procedure has a lower rate of postoperative ejaculatory dysfunction for small (30–80 cc) and large (80–150 cc) prostate glands.\(^1,7\)

Alternative surgical management options for men with larger prostates are limited. Simple open prostatectomy carries increased surgical risks and transurethral resective procedures for large prostates can be very long along with increased risk of bleeding, transfusions, and retreatment. Moreover, while holmium laser enucleation of the prostate (HoLEP) is globally accepted as a gold standard endoscopic treatment for large-volume prostates, its skillset and practice remain limited to few urologists.\(^5,9\) By leverage imaging, software, and robotics, Aquablation has standardized the procedure regardless of prostate size that results in a short learning curve and reproducible, consistent operating times.\(^10\) Herein, we report 3-year outcomes in men with larger (80–150 cc) prostates who underwent the Aquablation procedure as part of a prospective multicenter clinical trial.

METHODS

2.1 Trial design and participants

WATER II (NCT03123250) is a prospective, multicenter clinical trial conducted at 16 centers in the United States and Canada. Adult men age 45–80 were included if they had a prostate volume between 80 and 150 cc by transrectal ultrasound, baseline IPSS ≥ 12,\(^11\) a maximum urinary flow rate (Qmax) < 15 ml/s, a serum creatinine < 2 mg/dl, a history of inadequate or failed response to medical therapy and mental capability, and willingness to participate in the study. Men were excluded if they had body mass index ≥ 42 kg/m\(^2\), a history of prostate or bladder cancer, clinically significant bladder calculus or bladder diverticulum, active infection, previous urinary tract surgery, urinary catheter use daily for 90 or more days, chronic pelvic pain, diagnosis of urethral stricture, meatal stenosis or bladder neck contracture, use of anticholinergic agents, and other general conditions that could prevent adequate study follow-up. Patients with prior prostate surgery were not excluded. Men with urinary retention were excluded if the catheter was in place for more than 90 days. Each center obtained institutional review board/ethics committee approval prior to study start. Overall, 101 were enrolled in the original study at 16 sites. The 1-year study was extended during trial follow-up to include visits annually out to 5 years. Among the treated patients, 86 men agreed to long-term follow-up. The study was sponsored by the device manufacturer.

At baseline and selected follow-up visits, participants completed the following questionnaires: IPSS, Incontinence Severity Index, Pain Intensity Scale, International Index of Erectile Function (IIEF-15),\(^12\) the Male Sexual Health Questionnaire (MSHQ-EjD\(^13\)), uroflowmetry, and IPSS, Qmax, and treatment failure are reported at 3 years.

Results: The mean prostate volume was 107 cc (range 80–150). Mean IPSS improved from 23.2 at baseline to 6.5 at 3 years (16.3-point improvement, p < 0.0001). Mean IPSS quality of life improved from 4.6 at baseline to 1.1 at 3 years (improvement of 3.4 points, p < 0.0001). Maximum urinary flow increased from 8.7 to 18.5 cc/s. At 3 year follow-up, 6% of treated patients needed BPH medication and an additional 3% required surgical retreatment for LUTS.

Conclusions: Three-year follow-up demonstrates a sustained symptom reduction response along with low irreversible complications to Aquablation in men with LUTS due to BPH and prostates of 80–150 cc. Current treatment options available for men with prostates of this size have similar efficacy outcomes but are burdened with high rates of irreversible complications. There are now numerous clinical studies with Aquablation used in various prostate sizes, and it should be offered as an option to men with LUTS due to BPH.
and postvoid residual (PVR) volume measurements. Scheduled 3-year follow-up included PSA, uroflow, and IPSS questionnaires only as well as adverse event assessment. Surgical retreatment was defined as the need for a secondary procedure to treat prostatic tissue for recurrent LUTS.

The Aquablation procedure was performed using the AQUABEAM System (PROCEPT BioRobotics, Redwood City, California, USA). Briefly, after induction of general or spinal anesthesia, a 24F single-use handpiece was inserted into the prostatic urethra and secured into place using a bed-mounted arm. Using real-time transrectal ultrasound guidance, the surgeon defined the target anatomic resection contour on a computer console. Contours were selected to avoid damage to the bladder neck, ejaculatory ducts, and urinary sphincter. Furthermore, apical treatment was also planned ipsilaterally to ensure no injury to the verumontanum and its underlying ejaculatory ducts (butterfly cuts). Tissue was then treated utilizing an automated, robotic-executed, high-velocity waterjet with up to 2.4-cm treatment depth. For larger prostates, the Aquablation procedure typically required two treatment passes of the AQUABEAM probe for larger tissue removal.

Post-Aquablation, the bladder was irrigated using a 24–27 resectoscope sheath along with a Toomey syringe. Thereafter, hemostasis was delivered via low-pressure tamponade with a standard three-way 24 French hematuria Foley catheter inflated to 40–80 cc of saline either at the bladder neck (98 cases) or within the prostatic fossa (three cases), followed by continuous bladder irrigation as previously described, followed by use of the continuous traction device. The continuous traction device was designed for the specific purpose to hold catheter traction. Catheter traction was held for an average of 18 h in this study. Unlike contemporary Aquablation treatment series, it is noteworthy that no cases utilized electrocautery for hemostasis.

2.2 Data monitoring

All study data were collected using an electronic data capture system. Study data were 100% source-verified by study monitors.

2.3 Statistical analysis

Changes in continuous measures were assessed using t tests and/or repeated measures analysis of variance. Exact binomial methods were used to calculate confidence intervals for proportions. All statistical analysis was performed using R, and a p value of <0.05 was considered clinically significant.

3 RESULTS

In the original study, 101 men were enrolled at 16 sites (24 surgeons) between September and December 2017. Consent for study extension at all 16 sites was obtained in 86 subjects (85%). Baseline patient characteristics (n = 101) are summarized in Table 1. Mean age was 68 years (52–72) and baseline IPSS was 23 (12–35). Among the treated patients, 16 men (16%) had used a urinary catheter in the 45 days prior to enrollment. Mean prostate volume was 107 cc (80–150). A median lobe was present in 83% of cases with an average intravesical prostatic protrusion (IPP) distance of 1.8 cm (0.7–6.8). Study procedures were performed under general anesthesia in 18% and spinal anesthesia in 82% of cases. Mean operative time (defined as TRUS insertion to urinary catheter placement), Aquablation treatment time, and average number of treatment passes were 55 min (range 25–111 min), 8 min (range 3–17 min), and 1.8 passes (33% 1 pass, 56% 2 pass, and 10% 3 or more), respectively.

Three-year follow-up was obtained in 78 subjects (77%) (Figure 1). Follow-up may have been limited by the COVID-19 pandemic. Mean (SD) IPSS improved from 23.2 (6.3) at baseline to 6.5 (5.7) at 3 years (a 16.3-point improvement, p < 0.0001, Figure 2). Three-year IPSS scores were independent of both baseline IPSS and prostate size. IPSS QOL decreased from 4.6 (1.1) at baseline to 1.1 (1.4) at 3 years (a 3.4-point reduction, p < 0.0001). In patients reporting catheter use in the 45 days prior to enrollment, IPSS decreased from 26.3 (7.4) at baseline to 3.7 (2.4) at 3-year follow-up. No patient using a catheter prior to surgery has had to return to using a catheter postoperatively.

Maximum urinary flow rate increased from 8.7 (3.4) to 18.5 (13.8) cc/s (an improvement of 10.5 cc/s at 3 years, p < 0.0001), which was a sustained outcome achieved since the 3 month visit.

| TABLE 1 Baseline characteristics (n = 101) |
|-------------------------------------------|
| Characteristic                           | Statistic          |
| Age, years, mean (SD), range             | 67.5 (6.6), 52–79  |
| Body mass index, mean (SD), range        | 28.4 (4.2), 22–41  |
| Race                                      |                    |
| Asian                                    | 5 (5.0%)           |
| Black                                    | 6 (5.9%)           |
| White                                    | 88 (87.1%)         |
| Other                                    | 2 (2.0%)           |
| Ethnicity                                |                    |
| Hispanic or Latino                       | 9 (8.9%)           |
| Non-Hispanic or Latino                   | 92 (91.1%)         |
| Prostate specific antigen, g/dl; mean (SD), range | 7.1 (5.9), 0.34–29 |
| Use of catheters in 45 days prior to enrollment | 16 (15.8%)        |
| Prostate size (TRUS), cc; mean (SD), range | 107.4 (22.1), 80–150 |
| Middle lobe                              | 84 (83.2%)         |
| Intravesical component                   | 81 (96.4%)         |
| Intravesical protrusion, mm; mean (SD)   | 1.8 (0.8)          |
| Baseline questionnaires                  |                    |
| IPSS score, mean (SD), range             | 23.2 (6.3), 12–35  |
| IPSS QOL, mean (SD), range               | 4.6 (1.0), 2–6     |
| MSHQ-EJDA, mean (SD), range              | 8.2 (3.9), 1–15    |
| SHIM, mean (SD), range                   | 15.1 (7.4), 2–25   |

*Sexually active men only.
PVR urinary volume decreased from 131 (125) cc at baseline to 51 (63) cc at 3 years, which was a sustained outcome achieved since the 1 month visit. Mean (SD) serum PSA decreased from 7.1 (5.9) at baseline to 5.0 (6.0) at 3 years. In men not taking 5-ARI prior to surgery, PSA was decreased substantially at 36 months (p < 0.0001; Figure 3).

At 3-year follow-up, 6% of treated patients needed BPH medication and an additional 3% required surgical retreatment for LUTS. After Year 2, no subject underwent a surgical procedure for urethral stricture, bladder neck contracture, or urinary incontinence. The number of urologic events was small with no remarkable difference compared to previous results (Table 2).

Selected subgroup analysis was performed for patients with moderate symptoms (baseline IPSS score < 20), mean IPSS improved from 16.1 at baseline to 6 at 3 years (improvement of 10 points); for subjects with severe symptoms (baseline IPSS ≥ 20), mean IPSS improved from 26.9 to 6.8 at 3 years, an improvement of 20 points. The difference in 3-year scores between those with moderate versus severe baseline scores was not significant (p = 0.52). There were no differences in other efficacy measures between the subgroups.
Moreover, among the 16 catheter-dependent subjects within the 45 days prior to eligibility evaluation, IPSS improved from 26.3 at baseline to 3.7 at 3 years. This change was similar to that observed in men without baseline urinary retention. No subject with baseline urinary retention required catheter use following Aquablation. Two subjects (2%) experienced de novo, persistent incontinence requiring pad use following the Aquablation procedure that persisted to 1 year. One of the subjects exited the study at 1 year preventing any further updates on the status. The second patient has reported his incontinence has resolved.

### DISCUSSION

Our study provides strong evidence that the Aquablation procedure provides excellent rapid and sustained mid-term (3-year) relief of LUTS related to BPH. Importantly, improvement in BPH symptoms (IPSS, IPSS QOL) and uroflow measures (Qmax and PVR) were immediate, clinically meaningful and sustained to 3 years. Changes were consistent with an earlier randomized trial of Aquablation versus TURP in smaller (30–80 g) prostates but were especially notable in the current study given the larger prostate size enrolled (enrollment criteria of 80–150 cc, mean 107 cc, 83% with a large median lobe), a group that typically would require a simple prostatectomy or an enucleation procedure with associated risks of incision and transfusions for simple prostatectomy and a very steep learning curve for enucleation. In this early inaugural study, notably without use of any cautery for hemostasis, 5.9% of patients required a transfusion in recovery prior to discharge. No transfusion occurred in the operating room. In both situations of a transfusion or takeback for fulguration, the catheter tension device was not sufficient for complete hemostasis. Moreover, contemporary series of Aquablation advocate use of focal bladder neck cautery. A recently published series by Elterman et al from more than 2000 patients with a mean prostate size of 87 cc (range 20–363 cc) resulted in a transfusion rate of only 0.8% (95% CI 0.5%, 1.3%). These results compared favorably with other surgical approaches in larger sizes where the observed transfusions rates were TURP (4% to 14%), enucleation (0% to 5%), and simple prostatectomy.
FIGURE 3  PSA reduction in men grouped by 5-ARIs status prior to Aquablation

TABLE 2  Number of events, number of subjects with event, and rate by days since surgery

|                                | 0–6 months |                          | 6–12 months |                          | 12–36 months |                          |
|--------------------------------|------------|---------------------------|-------------|---------------------------|---------------|---------------------------|
|                                | Events     | Subjects                  | Rate (%     | Subjects                  | Rate (%     | Subjects                  |
|                                |            |                           | Subjects N = 101 |                          | Subjects N = 101 |                          |
| Bladder stones                 |            |                           | 3           | 3                         | 3.0%         | -                         |
| Bleeding*                      |            |                           | 7           | 6                         | 5.9%         | -                         |
| Transfusion, periprocedure     | 4          | 4                         | 4.0%        | -                         | -             | -                         |
| Transfusion, delayed (<30 days)| -          | -                         | -           | -                         | -             | -                         |
| Transfusion, delayed (>30 days)| -          | -                         | -           | -                         | -             | -                         |
| Takeback for fulguration       | 3          | 3                         | 3.0%        | -                         | -             | -                         |
| without transfusion            |            |                           | 2           | 2                         | 2.0%         | 5                         |
| Bleeding event not             |            |                           | 2           | 2                         | 2.0%         | 5                         |
| requiring transfusion or       |            |                           | 3           | 3                         | 3.0%         | -                         |
| takeback                       |            |                           | 1           | 1                         | 1.0%         | -                         |
| Cardiac                        | 3          | 3                         | 3.0%        | -                         | -             | -                         |
| Cerebrovascular accident       | 1          | 1                         | 1.0%        | -                         | -             | -                         |
| Chronic cystitis               | -          | -                         | -           | -                         | -             | -                         |
| Dysuria                        | 3          | 3                         | 3.0%        | -                         | -             | -                         |
| Ejaculatory dysfunction        | 15         | 15                        | 14.9%       | 1                         | 1.0%         | 2                         |
| Erectile dysfunction           | -          | -                         | -           | -                         | -             | 2                         |
| Hematospermia                  | -          | -                         | -           | 1                         | 1.0%         | -                         |
| Meatal stenosis                | 4          | 3                         | 3.0%        | -                         | -             | -                         |
| Multisystem organ failureb     | 1          | 1                         | 1.0%        | -                         | -             | -                         |

(Continues)
Further to safety-related outcomes, most incontinence events were acute, described as mixed incontinence, transient, and very few required the use of a pad. There were no late occurrences of incontinence reported in the study.

Improvements in LUTS were clinically important (mean ∼17-point reduction in IPSS, 3.4-point reduction in IPSS QOL) and concomitant large improvements were seen in uroflow measures (improvement in Qmax of 11 cc/s), both being durable at 3 years. Nearly all men were medication free (94%) at the end of 3 years. Freedom from surgical retreatment was 97% at 3 years. This compares favorably with two datasets published reporting freedom from surgical retreatment. Welk et al reported on 52 748 men undergoing TURP or PVP with an approximated 3-year freedom from surgical retreatment of 92% and 89%, respectively. Gilfrich et al reported on 43 041 men undergoing TURP, PVP, enucleation, or open simple prostatectomy with an approximated 3-year freedom from surgical retreatment of 93%, 89%, 94%, and 96%, respectively. Most importantly, these datasets include prostates of all sizes. Literature suggests the rates of retreatment are even higher in patients with glands larger than 80 g. The average patient undergoing a simple prostatectomy will stay 5 days in the hospital. Regarding operative time in large prostates, Nguyen et al reported data across a broad range of prostates sizes (30–300 cc) and showed Aquablation was the only option that could maintain a consistent operative time under 1 h whereas ThuLEP, HoLEP, GreenLEP, and PVP far exceeded the 1-h duration particularly in prostate sizes beyond 150 cc.

Advantages of our study include its prospective multicenter design with careful preoperative and scheduled postoperative visits and assessments. Prospective trials of men with large prostates and now 3-year follow-up are uncommon. A trial limitation was the lack of a control group, preventing direct comparisons with other treatment approaches. The level of evidence generated by Aquablation is establishing a new standard for LUTS due to BPH. At the time of this manuscript writing, there has not been any other surgical intervention, including MIST, to conduct two FDA clinical studies where at least one of them randomized against the gold standard TURP. From the three core clinical studies (WATER, WATER II, and OPEN WATER), Aquablation has demonstrated TURP-like efficacy in symptom reduction and uroflow improvement, yet in an unlimited prostate size range which is unattainable by a TURP surgeon. Additionally, the Aquablation efficacy is coupled with a risk profile for irreversible complications (incontinence, erectile dysfunction, and ejaculatory dysfunction) that are comparable with MIST procedures.

### CONCLUSION

The Aquablation procedure is a safe and effective, robotically executed and globally reproducible surgical option for the treatment of BPH-related LUTS in men with large prostate glands with continued...
durable outcomes at 3 years coupled with efficient operative times, limited hospitalization, and low retreatment rates.

ACKNOWLEDGMENT

The clinical study was funded by PROCEPT BioRobotics Corporation. Kevin C. Zorn, Mohamed Bidair, Eugene Kramolowsky, Mihir Desai, Dean Elterman, Claus Roehrborn, and Naem Bhojani have had in the past or currently have a consulting agreement with PROCEPT BioRobotics. Andrew Trainer, Andrew Arther, Leo Doumanian, Ronald P. Kaufman, Jr., James Lingeman, Amy Krambeck, Gregg Eure, Gopal Badlani, Mark Plante, Edward Uchio, Greg Sin, S. Larry Goldenberg, Ryan Paterson, Alan So, Mitchell Humphreys, Steven Kaplan, and Jay Motola have no disclosures with PROCEPT BioRobotics.

AUTHOR CONTRIBUTIONS

All authors on the manuscript were involved with recruiting, treating patients, and data collection. Kevin C. Zorn and Naem Bhojani led the manuscript effort.

ORCID

Kevin C. Zorn https://orcid.org/0000-0003-3651-6669
Mihir Desai https://orcid.org/0000-0002-3744-8234
Dean Elterman https://orcid.org/0000-0003-1507-7783
Mark Plante https://orcid.org/0000-0002-8874-9483
Naem Bhojani https://orcid.org/0000-0003-2679-2635

REFERENCES

1. Gilling P, Barber N, Bidair M, Anderson P, Sutton M, Aho T, et al. WATER: a double-blind, randomized, controlled trial of Aquablation™ vs transurethreal resection of the prostate in benign prostatic hyperplasia. J Urol. 2018 May;199(5):1252–61.
2. Bhojani N, Bidair M, Zorn KC, Trainer A, Arther A, Kramolowsky E, et al. Aquablation for benign prostatic hyperplasia in large prostates (80-150 cc): 1-year results. Urology. 2019 Jul;129:1–7.
3. Desai M, Bidair M, Bhojani N, Trainer A, Arther A, Kramolowsky E, et al. Aquablation for benign prostatic hyperplasia in large prostates (80–150 cc): 2-year results. Can J Urol. 2020 Apr;27(2):10147–53.
4. Bach T, Gilling P, El Hajj A, Anderson P, Barber N. First multi-center all-comers study for the Aquablation procedure. J Clin Med. 2020 Feb 24;9(2):603.
5. Misrai V, Rijo E, Zorn KC, Barry-Delongchamps N, Descavezad A. Waterjet ablation therapy for treating benign prostatic obstruction in patients with small- to medium-size glands: 12-month results of the first French Aquablation clinical registry. Eur Urol. 2019 Nov 1;76(5):667–75.
6. Gilling P, Barber N, Bidair M, Anderson P, Sutton M, Aho T, et al. Three-year outcomes after Aquablation therapy compared to TURP: results from a blinded randomized trial. Can J Urol. 2020 Feb;27(1):10072–9.
7. Desai M, Bidair M, Zorn KC, Trainer A, Arther A, Kramolowsky E, et al. Aquablation for BPH in large prostates (80-150cc): 6-month results from the WATER II Trial. BJU Int. 2019 Feb;81(1):e1498.
8. Robert G, Comu J-N, Fourmarier M, Saussine C, Descavezad A, Azzouzi A-R, et al. Multicentre prospective evaluation of the learning curve of holmium laser enucleation of the prostate (HoLEP). BJU Int. 2016 Mar;117(3):495–9.
9. Robles J, Pais V, Miller N. Mind the gaps: adoption and underutilization of holmium laser enucleation of the prostate in the United States from 2008 to 2014. J Endourol. 2020 Jul;34(7):770–6.
10. Ngyuen D-D, Misrai V, Bach T, Bhojani N, Lingeman JE, Elterman DS, et al. Operative time comparison of Aquablation, greenlight PVP, ThuLEP, GreenLEP, and HoLEP. World J Urol. 2020 Dec;38(12):3227–33.
11. Barry MJ, Fowler FJ, O’Leary MP, Bruskewitz RC, Holmgren HL, Mebusk WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992 Nov;148(5):1549–57. discussion 1564
12. Rosen RC, Allen KR, Xi X, Araujo AB. Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. Eur Urol. 2011 Nov;60(5):1010–6.
13. Rosen RC, Catania J, Pollack L, Althof S, O’Leary MP, Seftel AD. Male Sexual Health Questionnaire (MSHQ): scale development and psychometric validation. Urology. 2004 Oct;64(4):777–82.
14. Gilling P, Reuther R, Kahokehr A, Fraundorfer M. Aquablation - image-guided robot-assisted waterjet ablation of the prostate: initial clinical experience. BJU Int. 2016 Jun;117(6):923–9.
15. Desai M, Bidair M, Bhojani N, Trainer A, Arther A, Kramolowsky E, et al. WATER II (80-150 mL) procedural outcomes. BJU Int. 2018 Apr;25.
16. Elterman DS, Foller S, Ubrig B, Kugler A. Focal bladder neck cautery associated with low rate of post-Aquablation bleeding. Can J Urol. 2021;28(2):10611.
17. R Core Team. R: a language and environment for statistical computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2016. Available from: https://www.R-project.org/
18. Welk B, Reid J, Ordon M, Ravzi H, Campbell J. Population-based assessment of re-treatment and healthcare utilisation after photo-selective vapoporation of the prostate or electrosurgical transurethral resection of the prostate. BJU Int. 2019 Dec;124(6):1047–54.
19. Gilfrich C, May M, Fahlenbrach C, Günster C, Jeschke E, Popken G, et al. Surgical reintervention rates after invasive treatment for lower urinary tract symptoms due to benign prostatic syndrome: a comparative study of more than 43,000 patients with long-term followup. J Urol. 2021 Mar;205(3):855–63.
20. Pfitzenmaier J, Gilfrich C, Pritschi M, Herrmann D, Buse S, Haferkamp A, et al. Vaporization of prostates of > or <80 mL using a potassium-titanyl-phosphate laser: mid-term results and comparison with prostates of <80 mL. BJU Int. 2008 Aug;102(3):322–7.
21. Pariser JJ, Pearce SM, Patel SG, Bales GT. National trends of simple prostatectomy for benign prostatic hyperplasia with an analysis of risk factors for adverse perioperative outcomes. Urology. 2015 Oct 1;86(4):721–6.
22. Bhojani N, Yafi FA, Misrai V, Rijo E, Chughtai B, Zorn KC, et al. Review of sexual preservation after novel benign prostatic hyperplasia surgical treatment modalities from Food and Drug Administration Clinical Trials. Sex Med Rev. 2021 Jan;9(1):169–73.
23. Tanneru K, Jazayeri SB, Alam MU, Kumar J, Bazargani S, Kuntz G, et al. An indirect comparison of newer minimally invasive treatments for benign prostatic hyperplasia: a network meta-analysis model. J Endourol. 2021 Apr;35(4):409–16.

AUTHOR BIOGRAPHY

Dr. Kevin Zorn is a dual-board-certified (the United States and Canada), minimally invasive urologist, oncology-fellowship trained at the University of Chicago. As a native Montrealer, Dr. Zorn received his undergraduate and MD degrees from McGill University. After residencies in both Canada and the United States from 2008 to 2014. J Endourol. 2020 Jul;34(7):770–6.
University where he completed his residency in urology in 2005. His main focus of clinical and scientific interest is in the surgical treatment of benign prostatic hyperplasia (BPH) and prostate cancer. Over the past 10 years, Dr. Zorn has returned home to Montreal to develop the University of Montreal (CHUM) robotic and laser BPH program. He serves as Associate Professor of Surgery and Director of Robotic Surgery.

How to cite this article: Zorn KC, Bidair M, Trainer A, Arther A, Kramolowsky E, Desai M, et al. Aquablation therapy in large prostates (80–150 cc) for lower urinary tract symptoms due to benign prostatic hyperplasia: WATER II 3-year trial results. BJUI Compass. 2022;3(2):130–138. https://doi.org/10.1002/bco2.121